REMINDER: I AM POSTING A NEW TOPIC ABOUT ONCE A WEEK OR PERHAPS TWICE A WEEK. HOWEVER, IF YOU DON'T FIND A NEW TOPIC POSTED, THERE ARE AS OF MARCH 2013 OVER 900 TOPIC THREADS TO WHICH YOU CAN READ AND WRITE COMMENTS. I WILL BE AWARE OF EACH COMMENTARY AND MAY COME BACK WITH A REPLY.
TO FIND A TOPIC OF INTEREST TO YOU ON THIS BLOG, SIMPLY TYPE IN THE NAME OR WORDS RELATED TO THE TOPIC IN THE FIELD IN THE LEFT HAND SIDE AT TOP OF THE PAGE AND THEN CLICK ON “SEARCH BLOG”. WITH WELL OVER 900 TOPICS, MOST ABOUT GENERAL OR SPECIFIC ETHICAL ISSUES BUT NOT NECESSARILY RELATED TO ANY SPECIFIC DATE OR EVENT, YOU SHOULD BE ABLE TO FIND WHAT YOU WANT. IF YOU DON’T PLEASE WRITE TO ME ON THE FEEDBACK THREAD OR BY E-MAIL DoktorMo@aol.com
IMPORTANT REQUEST TO ALL WHO COMMENT ON THIS BLOG: ALL COMMENTERS WHO WISH TO SIGN ON AS ANONYMOUS NEVERTHELESS PLEASE SIGN OFF AT THE END OF YOUR COMMENTS WITH A CONSISTENT PSEUDONYM NAME OR SOME INITIALS TO HELP MAINTAIN CONTINUITY AND NOT REQUIRE RESPONDERS TO LOOK UP THE DATE AND TIME OF THE POSTING TO DEFINE WHICH ANONYMOUS SAID WHAT. Thanks. ..Maurice
FEEDBACK,FEEDBACK,FEEDBACK! WRITE YOUR FEEDBACK ABOUT THIS BLOG, WHAT IS GOOD, POOR AND CONSTRUCTIVE SUGGESTIONS FOR IMPROVEMENT TO THIS FEEDBACK THREAD
FDA Panel Backs Rationale for Over-the-Counter Mevacor
Today's FDA panel backed the rationale for OTC Mevacor. What the FDA will finally decide is yet to come.
From today'sBloomberg News Service
: "In today's deliberations before deciding whether to recommend that the FDA approve the application, the committee voted 25 to 0 to tell the agency that Merck and marketing partner Johnson & Johnson showed enough reason for using a 20-milligram dose of Mevacor to help people reduce their LDL, or bad, cholesterol, to a recommended level of less than 130 milligrams a deciliter.
The panel also voted 25 to 0 against recommending that the FDA require liver tests and found that the risk of muscle damage from the medication is ``acceptable.'' Statins reduce the liver's production of cholesterol, and the medicines also can cause muscle and kidney damage"
My question would be: what are the pharmaceutical affiliations of the members of the FDA panel and are they looking at the decision from a purely scientific and medically oriented point of view or also considering the financial implications of the switch? If, the latter, then their conclusions may be suspect and unethical. ..Maurice.